Table 1.
Characteristics of 2190 Danish patients with newly diagnosed symptomatic multiple myeloma and 21,900 matched population controls
| Myeloma patients | Population controls | ||
|---|---|---|---|
| Total | 2190 | 21,900 | |
| Gender, n (%) | Male | 1204 (55%) | 12,040 (55%) |
| Age (years) | Median (min, max) | 70 (19 – 98) | 70 (19–98) |
| Age >65 years, n (%) | 1425 (65%) | 14,250 (65%) | |
| M‐component, n (%) | IgA | 443 (20.8%) | – |
| IgG | 1184 (55.5%) | – | |
| IgM | 11 (0.5%) | – | |
| Free light chain | 339 (15.9%) | – | |
| Othera | 156 (7.4%) | – | |
| Missing | 57 | ||
| International staging system, n (%) | I | 497 (27.4%) | – |
| II | 651 (36.7%) | – | |
| III | 639 (34.9%) | – | |
| Missing | 403 | ||
| WHO performance status, n (%) | 0 | 502 (23.0%) | – |
| 1 | 888 (40.8%) | ||
| 2 | 442 (20.3%) | – | |
| ≥3 | 347 (15.9%) | – | |
| Missing | 11 | ||
| LDH, increased, n (%) | 463 (22.2%) | ||
| Missing | 104 | ||
| CRP, increased, n (%) | 809 (38.6%) | ||
| Missing | 92 | ||
| Creatinine, increased, n (%) | 770 (35.6%) | ||
| Missing | 27 | ||
| Comorbidity scoreb | 0 | 1294 (59.1%) | 14250 (65.1%) |
| 1 | 317 (14.5%) | 3278 (15.0%) | |
| 2 | 306 (14.0%) | 2403 (11.0%) | |
| ≥3 | 273 (12.5%) | 1969 (9.0%) |
a
Biclonal and nonsecretory myeloma.
b
Comorbidity classified according to Charlson Comorbidity Index (P < 0.0001).